Stock P/E, Current Price, and Intrinsic Value Over Time
Competitors of Gufic BioSciences Ltd
Stock Name
Market Cap
Current Price
High / Low
Stock P/E
Book Value
Dividend Yield
ROCE
ROE
Face Value
Industry Average
0 Cr
0
0
0
0%
0%
0%
0
Quarterly Result
Month
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Sales
128
167
132
251
194
172
162
165
175
177
173
195
215
Expenses
99
139
108
205
158
139
130
132
142
143
141
160
176
Operating Profit
29
27
24
46
36
33
33
33
33
34
32
35
39
OPM %
23%
16%
18%
18%
18%
19%
20%
20%
19%
19%
19%
18%
18%
Other Income
2
0
1
1
0
2
0
0
1
1
1
1
0
Interest
4
4
3
1
2
1
1
1
2
2
3
4
4
Depreciation
5
3
4
4
4
4
5
4
5
6
6
4
4
Profit before tax
23
20
17
42
30
29
26
28
27
27
24
28
31
Tax %
25%
24%
25%
25%
23%
27%
23%
26%
26%
25%
24%
26%
25%
Net Profit
17
15
13
31
23
21
20
21
20
20
18
21
23
EPS in Rs
2.23
1.99
1.65
3.22
2.41
2.17
2.09
2.17
2.08
2.10
1.87
2.13
2.39
Last Updated: August 9, 2024, 6:43 pm
Quarterly Chart
Profit & Loss - Annual Report
Last Updated: August 9, 2024, 6:43 pm
Month
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
TTM
Sales
81
98
121
148
201
245
306
351
379
488
779
691
785
Expenses
74
87
109
134
181
222
267
305
327
404
631
556
641
Operating Profit
7
11
12
14
20
23
39
46
52
84
148
135
143
OPM %
9%
11%
10%
10%
10%
9%
13%
13%
14%
17%
19%
20%
18%
Other Income
0
0
1
1
1
1
4
4
6
4
3
3
2
Interest
3
4
4
4
6
6
9
10
14
14
5
8
15
Depreciation
2
2
2
4
4
4
4
5
14
16
19
22
19
Profit before tax
3
5
6
7
10
14
30
35
30
58
127
107
112
Tax %
49%
37%
32%
36%
29%
37%
45%
38%
25%
23%
24%
25%
Net Profit
2
3
4
4
7
9
16
22
23
44
96
80
84
EPS in Rs
0.20
0.43
0.55
0.54
0.95
1.17
2.13
2.82
2.92
5.68
9.89
8.22
8.61
Dividend Payout %
25%
12%
9%
9%
5%
4%
2%
2%
2%
2%
1%
1%
Profit & Loss Yearly Chart
YoY Net Profit Growth
Year
2012-2013
2013-2014
2014-2015
2015-2016
2016-2017
2017-2018
2018-2019
2019-2020
2020-2021
2021-2022
2022-2023
YoY Net Profit Growth (%)
50.00%
33.33%
0.00%
75.00%
28.57%
77.78%
37.50%
4.55%
91.30%
118.18%
-16.67%
Change in YoY Net Profit Growth (%)
0.00%
-16.67%
-33.33%
75.00%
-46.43%
49.21%
-40.28%
-32.95%
86.76%
26.88%
-134.85%
Growth
Compounded Sales Growth
10 Years:
21%
5 Years:
18%
3 Years:
18%
TTM:
13%
Compounded Profit Growth
10 Years:
35%
5 Years:
32%
3 Years:
25%
TTM:
9%
Stock Price CAGR
10 Years:
36%
5 Years:
45%
3 Years:
29%
1 Year:
24%
Return on Equity
10 Years:
27%
5 Years:
27%
3 Years:
27%
Last Year:
20%
Last Updated: August 31, 2024, 3:31 am
Balance Sheet
Last Updated: August 9, 2024, 6:43 pm
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Equity Capital
8
8
8
8
8
8
8
10
10
10
10
10
Reserves
15
18
19
26
30
46
68
120
164
259
338
523
Borrowings
35
33
33
43
57
80
98
126
62
64
334
333
Other Liabilities
32
52
67
75
84
104
106
152
157
188
179
227
Total Liabilities
90
111
127
152
178
238
280
408
392
521
861
1,093
Fixed Assets
27
30
25
22
22
23
24
83
100
115
160
159
CWIP
3
0
0
0
0
2
10
31
13
41
170
307
Investments
0
0
0
0
0
0
0
0
0
0
1
2
Other Assets
60
81
102
130
156
213
245
294
279
365
531
625
Total Assets
90
111
127
152
178
238
280
408
392
521
861
1,093
Reserves and Borrowings Chart
Cash Flow
Month
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Cash from Operating ActivityÂ
5
11
11
-4
-4
-5
5
47
87
106
-27
-7
Cash from Investing ActivityÂ
-13
-3
-2
-1
-5
-9
-13
-43
-7
-95
-191
-102
Cash from Financing ActivityÂ
8
-7
-5
5
7
14
8
-4
-79
-6
234
82
Net Cash Flow
0
1
4
-0
-1
1
-0
0
2
5
17
-27
Free Cash Flow
Month
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Free Cash Flow
7.00
-24.00
-21.00
-19.00
-23.00
-34.00
-41.00
-52.00
-74.00
22.00
84.00
-199.00
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.
Undervalued: 23.35% compared to the current price ₹391.00
Intrinsic Value: 598.73
Calculation basis:
Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.
This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.
Undervalued: 53.13% compared to the current price ₹391.00
Last 5 Year EPS CAGR: 24.14%
*Investments are subject to market risks
Strength and Weakness
Strength
Weakness
The stock has a high average ROCE of 25.00%, which is a positive sign.
The company has higher reserves (135.50 cr) compared to borrowings (108.17 cr), indicating strong financial stability.
The company has shown consistent growth in sales (359.46 cr) and profit (41.85 cr) over the years.
The stock has a high average Working Capital Days of 94.75, which may not be favorable.
The stock has a high average Cash Conversion Cycle of 103.83, which may not be favorable.
Stock Analysis
Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Gufic BioSciences Ltd:
Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
ROE%: 16.17% (Industry Average ROE: 0%)
ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
Stock P/E: 45.4 (Industry average Stock P/E: 0)
Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
Total Debt / Equity: 0.59
Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions. Stock Rating:
About the Company - Qualitative Analysis
Gufic BioSciences Ltd. is a Public Limited Listed company incorporated on 23/07/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24100MH1984PLC033519 and registration number is 033519. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 779.16 Cr. and Equity Capital is Rs. 9.69 Cr. for the Year ended 31/03/2022.
INDUSTRY
ADDRESS
CONTACT
Pharmaceuticals
37, First Floor, Kamala Bhavan II, Mumbai Maharashtra 400069
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.
Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Gufic BioSciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Manage Consent
We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalized ads. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
